NervGen Pharma Corp. (NGEN) stock
NGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.90−0.06 (-3.06%)
Close on Nov 18, 2026Market cap $151.33MP/E –Yield –
NervGen Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
No operating income figures for NervGen Pharma
NervGen Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?